Therapeutic compounds and their use in cancer
View Patent ↗The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.
1. A compound of Formula I
wherein:
A is a substituted or unsubstituted indanone group;
B is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein A is a substituted indanone group having from 1-5 substituents independently chosen from acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkylthio, alkynyl, amino, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylalkoxy, aryloxy, arylthio, carbocycle, cyano, cyanato, halo, haloalkyl, halophenyl, hydroxyl, heteroaryl, heteroaryloxy, heterocycle, heteroarylalkoxy, isocyanato, isothiocyanato, nitro, sulfinyl, sulfonyl, sulfonamide, thiocarbonyl, thiocyanato, trihalomethanesulfonamido, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, and C-amido.
3. A compound of Formula I
wherein:
A is a substituted or unsubstituted indane group;
B is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
4. The compound of claim 3 , wherein A is a substituted indane group having from 1-5 substituents independently chosen from acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkylthio, alkynyl, amino, aryl, arylalkyl, arylalkenyl, arylalkynyl, arylalkoxy, aryloxy, arylthio, carbocycle, cyano, cyanato, halo, haloalkyl, halophenyl, hydroxyl, heteroaryl, heteroaryloxy, heterocycle, heteroarylalkoxy, isocyanato, isothiocyanato, nitro, sulfinyl, sulfonyl, sulfonamide, thiocarbonyl, thiocyanato, trihalomethanesulfonamido, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, and C-amido.
5. A compound of Formula I
wherein:
A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
B is a substituted or unsubstitued homopiperidine group;
R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
6. The compound of claim 5 , wherein B is a homopiperidine group substituted with one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)cycloalkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), amino acid (chosen from natural and non-natural amino acids), peptide having 1-5 amino acid residues (chosen from natural and non-natural amino acids), —C(═O)alkyl where the alkyl is substituted with one or more substituents (chosen from alkyl, amino, alkoxy, haloalkyl, haloalkoxy, nitro, cyano, hydroxyl, —COOH (and esters thereof), sulfonyl, sulfonamide) and sulfonyl.
7. The compound of claim 6 , wherein B is a homopiperidine group having one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), and sulfonyl.
8. The compound of claim 5 , wherein B is a homopiperidine group having one or more substituents chosen from —C(═O)CH 3 , —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —C(═O)OCH 2 CH 3 , —S(═O) 2 CH 3 , —S(═O) 2 CF 3 , —C(═O)OC(CH 3 ) 3 , C(═O)OCH 2 -phenyl, —CH 2 -phenyl, —CH(CH 3 ) 2 , —C(═O)NHCH 2 CH 3 , —C(═O)NHCH(CH 3 ) 2 , —C(═O)NHC(CH 3 ) 3 , —C(═O)NHCH 2 C(═O)OCH 2 CH 3 , —C(═O)C(CH 3 ) 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —C(═O)CH 2 C(CH 3 ) 3 , and cyclopentyl.
9. A compound of Formula I
wherein:
A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
B is a substituted or unsubstitued piperidine group attached to L 2 via the 2-, 3-, or 4-position;
R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
10. The compound of claim 9 , wherein B is a piperidine group substituted with one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)cycloalkyl, —C(═O)—NH- Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), amino acid (chosen from natural and non-natural amino acids), peptide having 1-5 amino acid residues (chosen from natural and non-natural amino acids), —C(═O)alkyl where the alkyl is substituted with one or more substituents (chosen from alkyl, amino, alkoxy, haloalkyl, haloalkoxy, nitro, cyano, hydroxyl, —COOH (and esters thereof), sulfonyl, sulfonamide) and sulfonyl.
11. The compound of claim 10 , wherein B is a piperidine group having one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), and sulfonyl.
12. The compound of claim 9 , wherein B is a piperidine group having one or more substituents chosen from —C(═O)CH 3 , —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —C(═O)OCH 2 CH 3 , —S(═O) 2 CH 3 , —S(═O) 2 CF 3 , —C(═O)OC(CH 3 ) 3 , C(═O)OCH 2 -phenyl, —CH 2 -phenyl, —CH(CH 3 ) 2 , —C(═O)NHCH 2 CH 3 , —C(═O)NHCH(CH 3 ) 2 , —C(═O)NHC(CH 3 ) 3 , —C(═O)NHCH 2 C(═O)OCH 2 CH 3 , —C(═O)C(CH 3 ) 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —C(═O)CH 2 C(CH 3 ) 3 , and cyclopentyl.
13. A compound of Formula I
wherein:
A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
B is a substituted or unsubstituted piperazine group;
R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0 or 1, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
14. The compound of claim 13 , wherein B is a piperazine group substituted with one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)cycloalkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), amino acid (chosen from natural and non-natural amino acids), peptide having 1-5 amino acid residues (chosen from natural and non-natural amino acids), —C(═O)alkyl where the alkyl is substituted with one or more substituents (chosen from alkyl, amino, alkoxy, haloalkyl, haloalkoxy, nitro, cyano, hydroxyl, —COOH (and esters thereof), sulfonyl, sulfonamide) and sulfonyl.
15. The compound of claim 14 , wherein B is a piperazine group having one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, COOH (and esters thereof), and sulfonyl.
16. The compound of claim 13 , wherein B is a piperazine group having one or more substituents chosen from —C(═O)CH 3 , —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —C(═O)OCH 2 CH 3 , —S(═O) 2 CH 3 , —S(═O) 2 CF 3 , —C(═O)OC(CH 3 ) 3 , —C(═O)OCH 2 -phenyl, —CH 2 -phenyl, —CH(CH 3 ) 2 , —C(═O)NHCH 2 CH 3 , —C(═O)NHCH(CH 3 ) 2 , —C(═O)NHC(CH 3 ) 3 , —C(═O)NHCH 2 C(═O)OCH 2 CH 3 , —C(═O)C(CH 3 ) 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —C(═O)CH 2 C(CH 3 ) 3 , and cyclopentyl.
17. A compound of Formula I
wherein:
A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
B is a substituted or unsubstituted pyrrolidine group attached to L 2 via the 3-position;
R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
18. The compound of claim 17 , wherein B is a pyrrolidine group substituted with one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)cycloalkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), amino acid (chosen from natural and non-natural amino acids), peptide having 1-5 amino acid residues (chosen from natural and non-natural amino acids), —C(═O)alkyl where the alkyl is substituted with one or more substituents (chosen from alkyl, amino, alkoxy, haloalkyl, haloalkoxy, nitro, cyano, hydroxyl, —COOH (and esters thereof), sulfonyl, sulfonamide) and sulfonyl.
19. The compound of claim 18 , wherein B is a pyrrolidine group having one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), and sulfonyl.
20. The compound of claim 17 , wherein B is a pyrrolidine group having one or more substituents chosen from —C(═O)CH 3 , —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —C(═O)OCH 2 CH 3 , —S(═O) 2 CH 3 , —S(═O) 2 CF 3 , —C(═O)OC(CH 3 ) 3 , C(═O)OCH 2 -phenyl, —CH 2 -phenyl, —CH(CH 3 ) 2 , —C(═O)NHCH 2 CH 3 , —C(═O)NHCH(CH 3 ) 2 , —C(═O)NHC(CH 3 ) 3 , —C(═O)NHCH 2 C(═O)OCH 2 CH 3 , —C(═O)C(CH 3 ) 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —C(═O)CH 2 C(CH 3 ) 3 , and cyclopentyl.
21. A compound of Formula I
wherein:
A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group;
B is a substituted or unsubstituted azetidine group R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, and halo;
L 1 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
L 2 can be saturated, partially saturated, or unsaturated, and is chosen from —(CH 2 ) n —(CH 2 ) n —, —(CH 2 ) n C(═O)(CH 2 ) n —, —(CH 2 ) n C(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═O)O(CH 2 ) n —, —(CH 2 ) n NC(═O)N(CH 2 ) n —, —(CH 2 ) n NC(═S)S(CH 2 ) n —, —(CH 2 ) n OC(═O)S(CH 2 ) n —, —(CH 2 ) n NH(CH 2 ) n —, —(CH 2 ) n O(CH 2 ) n —, —(CH 2 ) n S(CH 2 ) n —, and —(CH 2 ) n NC(═S)N(CH 2 ) n —, where each n is independently chosen from 0, 1, 2, 3, 4, 5, 6, 7, and 8, and wherein each carbon and nitrogen can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl;
and pharmaceutically acceptable salts thereof.
22. The compound of claim 21 , wherein B is an azetidine group substituted with one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)cycloalkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), amino acid (chosen from natural and non-natural amino acids), peptide having 1-5 amino acid residues (chosen from natural and non-natural amino acids), —C(═O)alkyl where the alkyl is substituted with one or more substituents (chosen from alkyl, amino, alkoxy, haloalkyl, haloalkoxy, nitro, cyano, hydroxyl, —COOH (and esters thereof), sulfonyl, sulfonamide) and sulfonyl.
23. The compound of claim 22 , wherein B is an azetidine group having one or more substituents chosen from hydro, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, nitro, —CH 2 -aryl, —C(═O)alkyl, —C(═O)—NH-Alkyl, cycloalkyl, hydroxyl, —COOH (and esters thereof), and sulfonyl.
24. The compound of claim 21 , wherein B is an azetidine group having one or more substituents chosen from —C(═O)CH 3 , —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —C(═O)OCH 2 CH 3 , —S(═O) 2 CH 3 , —S(═O) 2 CF 3 , —C(═O)OC(CH 3 ) 3 , C(═O)OCH 2 -phenyl, —CH 2 -phenyl, —CH(CH 3 ) 2 , —C(═O)NHCH 2 CH 3 , —C(═O)NHCH(CH 3 ) 2 , —C(═O)NHC(CH 3 ) 3 , —C(═O)NHCH 2 C(═O)OCH 2 CH 3 , —C(═O)C(CH 3 ) 3 , —CH(CH 3 ) 2 , —CH 2 CH(CH 3 ) 2 , —C(═O)CH 2 C(CH 3 ) 3 , and cyclopentyl.
25. The compound of claim 9 , wherein L 1 is —S—.
26. The compound of claim 9 , wherein L 2 is —(CH 2 ) n —(CH 2 ) n —, and each n is independently chosen from 0, 1, 2, and 3 and wherein each carbon can be optionally substituted with one or more substituents independently chosen from hydroxyl, halo, alkoxy, alkyl, amino, —NR 2 R 3 , —NSO 2 R 4 , —NC(═O)NR 2 R 3 , heteroaryl, aryl, cycloalkyl, and heterocyclic; wherein —R 2 and —R 3 are independently chosen from —H, alkyl, and —C(═O)OR 4 ; and wherein R 4 is C 1 -C 4 alkyl.
27. The compound of claim 9 , wherein R1 is hydro.
28. A compound chosen from 9-[2-(1-Acetylpiperidin-4-yl)ethyl]-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-6-amine, 4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl}ethyl)piperidine-1-carbaldehyde, 4-(2-{6-Amino-8-[(7-bromo-2,3-dihydro-1,4-benzodioxin-6-yl)thio]-9H-purin-9-yl}ethyl)piperidine-1-carbaldehyde, 9-(3-Amino-3-cyclopropylpropyl)-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-6-amine, 9-(3-Amino-3-cyclohexylpropyl)-8-[(6-bromo-,3-benzodioxol-5-yl)thio]-9H-purin-6-amine, (2S)-1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl}ethyl)piperidin-1-yl]-1-oxopropan-2-ol, 4-(2-{6-Amino-8-[(1-oxo-2,3-dihydro-1H-inden-5-yl)thio]-9H-purin-9-yl}ethyl)piperidine-1-carbaldehyde, 2-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-oxoethanol, and 6-({9-[2-(1-Acetylpiperidin-4-yl)ethyl]-6-amino-9H-purin-8-yl}thio)-1,3-benzodioxole-5-carbonitrile.
29. A compound chosen from 8-(2,5-dimethoxy-phenylsulfanyl)-9-phenethyl-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(3-phenyl-propyl)-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-phenethyl-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-phenyl-propyl)-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(4-nitro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(4-nitro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(4-fluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(4-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(4-fluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(4-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-phenethyl-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 8-(2,4-dimethoxy-phenylsulfanyl)-9-phenethyl-9H-purin-6-ylamine, 8-(2,4-dimethoxy-phenylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 8-(4-chloro-phenylsulfonyl)-9-phenethyl-9H-purin-6-ylamine, 8-(4-chloro-phenylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 4-(6-amino-9-phenethyl-9H-purin-8-ylsulfanyl)-benzonitrile, 4-(6-amino-3-phenethyl-3H-purin-8-ylsulfanyl)-benzonitrile, 9-[2-(3,4-dimethoxy-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(3,4-dimethoxy-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-p-tolyl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-p-tolyl-ethyl)-3H-purin-6-ylamine, 9-[2-(2-chloro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2-chloro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-[2-(2,4-dichloro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2,4-dichloro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenyl-sulfanyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2-fluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 9-[2-(4-chloro-phenyl)-ethyl]-8-(3,4,5-trimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(4-chloro-phenyl)-ethyl]-8-(3,4,5-trimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(-6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-phenethyl-9H-purin-6-ylamine, 8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-methoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3-methoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-fluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(4-chloro-2-fluorophenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-pentafluorophenyl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-pentafluorophenyl-ethyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-phenyl-propyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(3-phenyl-propyl)-3H-purin-6-ylamine, 9-phenethyl-8-(3,4,5-trimethoxy-phensulfanyl)-9H-purin-6-ylamine, 3-phenethyl-8-(3,4,5-trimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-(3-phenyl-propyl)-8-(3,4,5-trimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-(3-phenyl-propyl)-8-(3,4,5-trimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-pyrrol-1-yl-ethyl)-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-pyrrol-1-yl-ethyl)-3H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-pyrrol-1-yl-propyl)-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-3-(3-pyrrol-1-yl-propyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(2-chloro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(2-chloro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2,4,6-trimethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2,4,6-trimethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-phenyl-butyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-phenyl-butyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[1-(4-methoxy-phenyl)-cyclopropylmethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[1-(4-methoxy-phenyl)-cyclopropylmethyl]-3H-purin-6-ylamine, 9-[1-(4-chloro-phenyl)-cyclobutylmethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[1-(4-chloro-phenyl)-cyclobutylmethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 1-(4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-ethyl}-phenyl)-ethanone, 1-(4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-3-yl]-ethyl}-phenyl)-ethanone, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-pyrrol-1-yl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-pyrrol-1-yl-ethyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-naphthalen-1-yl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-naphthalen-1-yl-ethyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-o-tolyl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-o-tolyl-ethyl)-3H-purin-6-ylamine, 9-[2-(4-bromo-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(4-bromo-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-[2-(2,3-dichloro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2,3-dichloro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 4-{2-[6-Amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-ethyl}-phenol, 4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-ethyl}-phenol, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-trifluoromethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3-trifluoromethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-ethyl}-benzoic acid, 4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-3-yl]-ethyl}-benzoic acid, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(4-fluoro-benzyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(4-nitro-benzyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2-methoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2-methoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-phenyl-butyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-phenyl)-butyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(2,4,6-trimethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(2,4,6-trimethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[1-(4-chloro-phenyl)-cyclobutylmethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[1-(4-chloro-phenyl)-cyclobutylmethyl]-3H-purin-6-ylamine, 9-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(4-chloro-2-fluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-methyl-2-phenyl-pentyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(3-methyl-2-phenyl-pentyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-cyclopentyl-2-phenyl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-cyclopentyl-2-phenyl-ethyl)-3H-purin-6-ylamine, 9-(2-cyclopentyl-2-phenyl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-(2-cyclopentyl-2-phenyl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(3-methyl-2-phenyl-pentyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(3-methyl-2-phenyl-pentyl)-3H-purin-6-ylamine, 2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-1-(2,4-dichloro-phenyl)ethanol, 2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-3-yl]-1-(2,4-dichloro-phenyl)ethanol, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(3-fluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-ethoxy-4-methoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-Dimethoxy-phenylsulfanyl)-9-(3-methyl-2-phenyl-butyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(3-methyl-2-phenyl-butyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2,5-dimethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2,5-dimethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(3-ethoxy-4-methoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 9-[2-(4-Chloro-phenyl)-3-methyl-butyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purine-6-ylamine, 3-[2-(4-chloro-phenyl)-3-methyl-butyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purine-6-ylamine, 9-[2-(2,4-difluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purine-6-ylamine, 9-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purine-6-ylamine, 3-[2-(2-chloro-6-fluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purine-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(2,5-dimethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(2,5-dimethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-methyl-2-phenyl-butyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(3-methyl-2-phenyl-butyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3,5-dimethyl-phenyl)-ethyl]-9H-purine-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3,5-dimethyl-phenyl)-ethyl]-3H-purine-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-pyridin-4-yl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-pyridin-2-yl-ethyl)-9H-purin-6-ylamine, 8-(2,5-Dimethoxy-phenylsulfanyl)-3-(2-pyridin-2-yl-ethyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-iodo-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(3-iodo-phenyl)-ethyl]-3H-purin-6-ylamine, 9-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2-chloro-4-fluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-[2-(2-bromo-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2-bromo-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-[2-(3,5-difluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(3,5-difluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-[2-(2,3-difluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2,3-difluoro-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(6-Bromo-1,3-benzodioxol-5-ylsulfanyl)-9-[2-(2-fluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(2-fluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(2-bromo-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(2-bromo-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-pyridin-3-yl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-pyridin-3-yl-ethyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(3-iodo-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3-iodo-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-o-tolyl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-o-tolyl-ethyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-naphthalen-1-yl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-naphthalen-1-yl-ethyl)-3H-purin-6-ylamine, 1-(4-{2-[6-amino-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-9-yl]-ethyl}-phenyl)-ethanone, 1-(4-{2-[6-amino-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-3-yl]-ethyl}-phenyl)-ethanone, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(2,3-difluoro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-1,3-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(2,3-difluoro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-p-tolyl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-p-tolyl-ethyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(3-trifluoromethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3-trifluoromethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 9-(2-benzo[1,3]dioxol-5-yl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-(2-benzo[1,3]dioxol-5-yl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-(2-cyclohexyl-ethyl)-8-(2,5-dimethoxyphenyl-sulfanyl)-9H-purin-6-ylamine, 3-(2-cyclohexyl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-(2-biphenyl-4-yl-ethyl)-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine, 3-(2-biphenyl-4-yl-ethyl)-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3H-purin-6-ylamine, 4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-ethyl}-benzenesulfonic acid, 4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-3-yl]-ethyl}-benzenesulfonic acid, 2-[6-Amino-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-9-yl]-1-(2,4-dichloro-phenyl)-ethanol, 2-[6-amino-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-3-yl]-1-(2,4-dichloro-phenyl)-ethanol, 9-(2-Cyclohexyl-2-phenyl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-(2-cyclohexyl-2-phenyl-ethyl)-8-(2 5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-(2-biphenyl-4-yl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-(2-biphenyl-4-yl-ethyl)-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2-trifluoromethyl-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2-trifluoromethyl-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(4-dimethylamino-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(4-dimethylamino-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(4-dimethylamino-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(4-dimethylamino-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-diethoxy-phenylsulfanyl)-9-phenethyl-9H-purin-6-ylamine, 8-(2,5-diethoxy-phenylsulfanyl)-3-phenethyl-3H-purin-6-ylamine, 9-[2-(2-chloro-phenyl)-ethyl]-8-(2,5-diethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(2-chloro-phenyl)-ethyl]-8-(2,5-diethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 9-[2-(3,5-dimethoxy-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 3-[2-(3,5-dimethoxy-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[2-(3,5-dimethoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3,5-dimethoxy-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-thiophen-3-yl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-thiophen-3-yl-ethyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-2-thiophen-2-yl-ethyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-(2-thiophen-2-yl-ethyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-thiophen-3-yl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-thiophen-3-yl-ethyl)-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(2-thiophen-2-yl-ethyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-(2-thiophen-2-yl-ethyl)-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2-nitro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2-nitro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(2-nitro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-3-[2-(2-nitro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylmethyl)-9-phenethyl-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylmethyl)-3-phenethyl-3H-purin-6-ylamine, (4-{2-[6-amino-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-9-yl]-ethyl}-phenyl)carbamic acid tert-butyl ester, (4-{2-[6-amino-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-3-yl]-ethyl}-phenyl)carbamic acid tert-butyl ester, 9-[2-(4-amino-phenyl)-ethyl]-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine, (4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-9-yl]-ethyl}-phenyl)-carbamic acid tert-butyl ester, (4-{2-[6-amino-8-(2,5-dimethoxy-phenylsulfanyl)-purin-3-yl]-ethyl}-phenyl)-carbamic acid tert-butyl ester, 9-[2-(4-amino-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-trifluoromethoxy-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-(2-pentafluorophenyl-ethyl)-9H-purin-6-ylamine, 9-[2-(3,5-bistrifluoromethyl-phenyl)-ethyl]-8-(2,5-dimethoxy-phenylsulfanyl)-9H-purin-6-ylamine, 9-[2-(3,5-Bistrifluoromethyl-phenyl)-ethyl]-8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-[1-(4-chloro-phenyl)-cyclopropylmethyl]-9H-purin-6-ylamine, 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-3-[2-(3-nitro-phenyl)-ethyl]-3H-purin-6-ylamine, 8-(2,5-dimethoxy-phenylsulfanyl)-9-[2-(3-nitro-phenyl)-ethyl]-9H-purin-6-ylamine, 8-(benzo[1,3]dioxol-5-ylsulfanyl)-9-phenethyl-1,9-dihydro-purin-6-one, and 8-(6-bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-phenethyl-1,9-dihydro-purin-6-one.
30. A compound according to claim 28 , wherein said compound is 9-[2-(1-Acetylpiperridin-4-yl)ethyl]-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-6-amine.
31. A compound according to claim 28 , wherein said compound is 4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl}ethyl)piperidine-1-carbaldehyde.
32. A compound according to claim 28 , wherein said compound is (2S)-1-]4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl}ethyl)piperidin-1-yl]-1-oxopropan-2-ol.
33. A compound according to claim 28 , wherein said compound is 2-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)thio]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-oxoethanol.
34. A compound according to claim 28 , wherein said compound is 6-({9-[2-(1-Acetylpiperidin-4-yl)ethyl]-6-amino-9H-purin-8-yl}thio)-1,3-benzodioxole-5-carbonitrile.